Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center, Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  gastrointestinal cancer
Results 1-25 of 5213 for your search:
Start Over
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Ropidoxuridine in Treating Patients with Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9882, NCI-2015-00258, BRUOG 265, NCT02381561
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
Creative Writing Intervention in Improving the Psychological Effect of Cancer in Patients with Advanced Lung or Gastrointestinal Cancer
Status: Active
Phase: No phase specified
Type: Supportive care
Age: Not specified
Trial IDs: D15113, NCI-2016-00373, NCT02575898
Capecitabine in Treating Patients with Metastatic Breast Cancer or Advanced/Metastatic Gastrointestinal Cancers
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-IIT-X7-7, NCI-2016-00409, STUDY00002962, NCT02595320
Electronic Activity Monitoring in Assessing Functional Activity in Patients with Gastrointestinal Cancer Undergoing Chemotherapy
Status: Active
Phase: No phase specified
Type: Natural history/Epidemiology
Age: 18 and over
Trial IDs: 16-493, NCI-2016-01608, NCT02909062
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
Pembrolizumab and Hsp90 inhibitor XL888 in Treating Patients with Advanced Gastrointestinal Cancer
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Winship3321-16, NCI-2016-01594, IRB00087397, NCT03095781
Blood and Tumor Tissue Samples Collected from Patients with Gastrointestinal Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 18 and over
Trial IDs: 11-C-0112, NCI-2015-01225, P10747, 311713, NCT01313442
Mutation-Targeted Therapy with Sunitinib Malate or Everolimus in Treating Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal Tract or Pancreas
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0040, NCI-2015-00091, 339636, P141605, 150040, NCT02315625
Ph 1 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: POLARIS2013-001, NCI-2017-00851, NCT02102022
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients with Metastatic Gastrointestinal Tumors
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0152, NCI-2016-01058, NCT02757391
Iobenguane I-131 and Yttrium Y 90-Edotreotide in Treating Patients with Midgut Neuroendocrine Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201608857, NCI-2017-00636, NCT03044977
Long-Term Follow up for Patients Previously Enrolled in National Cancer Institute Surgery Branch Studies
Status: Enrolling by invitation
Phase: No phase specified
Type: Natural history/Epidemiology
Age: 16 and over
Trial IDs: 09-C-0161, NCI-2015-01184, 090161, 304795, 344944, P09518, NCT00923026
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 18 and over
Trial IDs: CGI-061, NCI-2013-01950, NCT02092714
68Ga-DOTA-JR11and 177Lu-DOTA-JR11 PET/CT in Diagnosing and Treating Patients with Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 15-161, NCI-2015-02110, NCT02609737
Regorafenib in Treating Patients with Advanced or Metastatic Neuroendocrine Tumors
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0S-14-3, NCI-2014-01996, HS-14-00583, NCT02259725
Pembrolizumab in Treating Patients with Previously Treated Metastatic High Grade Neuroendocrine Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GI-087, NCI-2016-01492, NCT02939651
A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI401-101, NCI-2015-02290, NCT02432326
Meditation with or without End of Life Planning Video in Managing Stress in Caregivers of Patients with Stage IV Gastrointestinal Cancer
Status: Active
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: CASE4815, NCI-2016-01613, NCT02842047
Domperidone in Treating Patients with Gastrointestinal Disorders
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 and over
Trial IDs: 2012-0261, NCI-2012-02093, NCT01696734
Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GRN1201-001, NCI-2016-01132, NCT02696356
Surgery or Non-surgical Management in Treating Patients with Intra-abdominal Cancer and Bowel Obstruction
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: S1316, NCI-2014-01497, SWOG/S1316, NCT02270450
Embolization Therapy with or without Chemotherapy in Controlling Liver Metastases in Patients with Neuroendocrine Tumor Metastases to the Liver That Cannot Be Removed by Surgery
Status: Active
Phase: Phase III
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: UPCC01215, NCI-2016-00610, NCT02724540
Start Over